CORT CORCEPT THERAPEUTICS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1088856 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY30.0%
TTM net income YoY52.9%
TTM EPS YoY52.9%
Revenue 3-yr CAGR28.9%
Net income 3-yr CAGR21.1%
Margins
Gross margin98.5%
Operating margin11.5%
Net margin16.8%
FCF margin20.2%
EBITDA margin11.8%
Returns
ROE22.1%
ROA17.5%
ROIC (approx.)17.9%
Asset turnover1.04x
Leverage & solvency
Liabilities / assets19.4%
Debt / equity0.00x
Current ratio3.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.22x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $761.41M | $675.04M |
| Cost of revenue | $12.98M | $10.88M |
| Gross profit | $748.43M | $664.16M |
| R&D expense | $254.91M | $246.89M |
| SG&A expense | $448.73M | $280.32M |
| Operating income | $44.80M | $136.95M |
| Pretax income | $66.46M | $161.49M |
| Income tax | -$33.19M | $20.28M |
| Net income | $99.65M | $141.21M |
| EBITDA | $45.95M | $137.75M |
| EPS (basic) | 0.95 | 1.35 |
| EPS (diluted) | 0.82 | 1.23 |
| Weighted avg. shares (diluted) | 119.99M | 113.48M |
| Balance sheet | ||
| Cash & equivalents | $120.50M | $128.66M |
| Short-term investments | $251.66M | $255.67M |
| Receivables | $59.79M | $53.98M |
| Inventory | $12.87M | $12.41M |
| Current assets | $485.46M | $471.60M |
| PP&E, net | $1.89M | $2.69M |
| Total assets | $836.65M | $840.55M |
| Current liabilities | $166.09M | $140.77M |
| Total liabilities | $188.85M | $160.96M |
| Shareholders' equity | $647.80M | $679.59M |
| Shares outstanding | 105.97M | 105.11M |
| Cash flow statement | ||
| Operating cash flow | $142.00M | $198.29M |
| Capital expenditure | $211,000 | $2.17M |
| Free cash flow | $141.78M | $196.12M |
| Investing cash flow | $69.76M | -$177.60M |
| Financing cash flow | -$220.37M | -$28.35M |
| Depreciation & amortization | $1.15M | $795,000 |
| Stock-based compensation | $84.50M | $61.35M |
| Share buybacks | $172.91M | $15.66M |
Free plan shows the latest 2 periods; Pro shows all 26 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.